Serum neuron-specific enolase and S100 calcium binding protein B biomarker levels do not improve diagnosis of acute stroke

González-García, Sergio; González‐Quevedo, Alina; Peña-Sánchez, Marisol; Menéndez-Saínz, Caridad; Fernández-Carriera, Rebeca; Arteche-Prior, Marianela; Pando-Cabrera, A; Fernández-Concepción, O

doi:10.4997/jrcpe.2012.302

Cited by 19 publications

(6 citation statements)

References 19 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, no control group of patients without CNS disorders was examined. Another recent study found only a low sensitivity of 55% for detecting stroke in a mixed IS and ICH population when analyzing S100β in a 12- to 48-h time window since symptom onset [32]. It is unclear whether these discrepancies are caused by different preanalytical procedures or by the assays used to detect S100β.…”

Section: Discussionmentioning

confidence: 99%

Serum Protein S100β is a Diagnostic Biomarker for Distinguishing Posterior Circulation Stroke from Vertigo of Nonvascular Causes

et al. 2014

View full text Add to dashboard Cite

Background: In patients presenting with acute vertigo or dizziness, identifying the posterior fossa stroke as the underlying cause can be a major challenge. We therefore evaluated the serum biomarkers for the differential diagnosis of nonvascular vertigo and posterior circulation stroke. Methods: Of a total of 80 patients, 31 patients had an ischemic stroke in the posterior circulation and 12 infratentorial hemorrhage. Findings in these patients were compared with those in 22 patients with vertigo of nonvascular origin and 15 matched control patients without neurological symptoms. Blood samples drawn <24 h after symptom onset were analyzed for S100 calcium-binding protein B (S100β), matrix metalloproteinase 9 (MMP-9), soluble vascular cellular adhesion molecule-1 (sVCAM-1), and glial fibrillary acidic protein (GFAP). Results/Conclusion: Serum levels of S100β were significantly higher in stroke patients than in nonvascular vertigo patients. Serum concentrations of MMP-9 tended to be higher in stroke patients, whereas no significant differences among groups were found for sVCAM-1 and GFAP. Receiver-operating characteristic analysis revealed a sensitivity of 94.4% and a specificity of 31.8% for detecting stroke in patients presenting with vertigo for S100β. S100β may serve as a biomarker for distinguishing between vertigo of vascular causes and nonvascular, acute vertigo.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum Protein S100β is a Diagnostic Biomarker for Distinguishing Posterior Circulation Stroke from Vertigo of Nonvascular Causes

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In a study with 61 acute stroke patients, González‐García S. et al showed that blood S100β was elevated in stroke patients between 12 and 48 h after symptoms onset compared with high‐risk controls. Although its levels did not correlate with severity, it could discriminate ( p < .001) between lacunar and non‐lacunar IS 68 . Additionally, Foerch et al 69 measured the protein kinetics and showed that peak values can occur until 96 h after symptoms.…”

Section: Resultsmentioning

confidence: 99%

Fluid biomarkers in stroke: From animal models to clinical care

Dias

Silva

Moura

et al. 2022

Acta Neuro Scandinavica

View full text Add to dashboard Cite

Stroke is a leading cause of death and disability worldwide. Stroke prevention, early diagnosis, and efficient acute treatment are priorities to successfully impact stroke death and disability. Fluid biomarkers may improve stroke differential diagnostic, patient stratification for acute treatment, and post‐stroke individualized rehabilitation. In the present work, we characterized the use of stroke animal models in fluid biomarker research through a systematic review of PubMed and Scopus databases, followed by a literature review on the translation to the human stroke care setting and future perspectives in the field. We found increasing numbers of publications but with limited translation to the clinic. Animal studies are very heterogeneous, do not account for several human features present in stroke, and, importantly, only a minority of such studies used human cohorts to validate biomarker findings. Clinical studies have found appealing candidates, both protein and circulating nucleic acids, to contribute to a more personalized stroke care pathway. Still, brain tissue complexity and the fact that different brain pathologies share lesion biomarkers make this task challenging due to biomarker low specificity. Moreover, the study design and lack of validation cohorts may have precluded a formal integration of biomarkers in different steps of stroke diagnosis and treatment. To overcome such issues, recent pivotal studies on biomarker dynamics in individual patients are providing added value to diagnosis and anticipating patients' early prognosis. Presently, the most consistent protein biomarkers for stroke diagnosis and short‐ and long‐term prognosis are associated with tissue damage at neuronal (TAU), axonal (NFL), or astroglial (GFAP and S100β) levels. Most promising nucleic acids are microRNAs (miR), due to their stability in plasma and ease of access. Still, clinical validation and standardized quantitation place them a step behind compared protein as stroke biomarkers. Ultimately, the definition of clinically relevant biomarker panels and optimization of fast and sensitive biomarker measurements in the blood, together with their combination with clinical and neuroimaging data, will pave the way toward personalized stroke care.

show abstract

“…[12,23]. Although S100B been linked to cerebral ischaemia, developing it into a biomarker for differential diagnosis in clinical practice has been problematic [24,25]. Several writers have claimed that elevated levels of S100B in the blood are not unique to stroke, claiming that the rise occurs in other neurological disorders with similar symptoms [26].…”

Section: Discussionmentioning

confidence: 99%

"Biomarker of Cerebral Injury S100 During Carotid Endarterectomy"

Makovec¹

2022

BJSTR

View full text Add to dashboard Cite

Background:The aim of this pilot investigation was to see if a raised serum S100B level or a decrease in rSO 2 following carotid revascularization with CEA might be used to detect neurological instability in CEA patients. Increased serum S100B levels during CEA, we hypothesized, would be linked to neurological symptoms after surgery. Patients and methods: A total of 64 consecutive CEAs in 60 patients operated under LA (local anesthesia) during an 18-month period were prospectively evaluated. The cerebral oximeter was used to measure cerebral oxygen saturation (rSO2) before and after cross-clamping along with serum. concentration of S100B protein. Selective shunting was performed when neurological changes occurred, regardless of NIRS. Results:The neurological symptoms that occurred after clamping correlated with an increase in the serum level of S100B (P = .040). The cut-off of 22.5% of S100B increase was determined to be optimal for identifying patients with neurological symptoms. There was no correlation between rSO 2 decline and neurological symptoms (P = .675). Two (3.1%) perioperative strokes occurred.Conclusions: Awake neuromonitoring has been found to provide a sensitive and direct evaluation of brain tissue perfusion and is specific to CEA under LA. Although there was a favourable connection between CEA and an increase in serum S100B protein, due to the long assessment time, serum S100B monitoring was not practicable (usually 3 hours).

show abstract

Serum neuron-specific enolase and S100 calcium binding protein B biomarker levels do not improve diagnosis of acute stroke

Cited by 19 publications

References 19 publications

Serum Protein S100β is a Diagnostic Biomarker for Distinguishing Posterior Circulation Stroke from Vertigo of Nonvascular Causes

Serum Protein S100β is a Diagnostic Biomarker for Distinguishing Posterior Circulation Stroke from Vertigo of Nonvascular Causes

Fluid biomarkers in stroke: From animal models to clinical care

"Biomarker of Cerebral Injury S100 During Carotid Endarterectomy"

Contact Info

Product

Resources

About